BioMarin Pharmaceutical Inc. (BMRN)
BMRNNASDAQ-GSBiotechnology: Pharmaceutical Preparations
$57.13
-0.0500 (-0.09%) today
At the close, Nov 10, 4:00 PM ET. After hours $57.05 -0.14%
- Market cap
- $11.07bn
- P/E
- 32.1
- EPS, last 4 quarters
- $1.78
- Dividend yield
- –
- Day range
- $56.38 to $57.37
- 52-week range
- $49.26 to $70.98
- Average volume
- 2.30m
- Previous close
- $57.18
Analysts
24 coveringBuy18 buy, 6 hold, 0 sell
Targets a year out average $88.00, +54.0% from here
Earnings
next estimate $0.7000Next report
Dec 2025
+300.0%
Mar 2026
-25.6%
Jun 2026
+13.9%
Sep 2026
+106.7%
estimate reported, and the surprise
Financials
| Quarter | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| Revenue | $874.57m | $766.21m | $989.71m | $1.02bn |
| Gross profit | $598.86m | $571.21m | $786.91m | $819.23m |
| Operating income | -$44.61m | $129.64m | $110.92m | -$82.08m |
| Net income | -$46.57m | $105.53m | $44.76m | -$122.83m |
Last four quarters: revenue $3.66bn, margin -0.5%, free cash flow $557.86m
News
8 latest- BioMarin (BMRN) Q3 2026 Earnings Call TranscriptThe Motley Fool · Nov 2, 2026
- BioMarin Pharmaceutical Q3 Earnings Call HighlightsMarketBeat · Nov 2, 2026
- BioMarin (BMRN) Q3 Earnings: Taking a Look at Key Metrics Versus EstimatesZacks · Nov 2, 2026
- BioMarin Pharmaceutical (BMRN) Q3 Earnings Surpass EstimatesZacks · Nov 2, 2026
- BioMarin Inks $475M License Deal For Investigational Fabry Disease Therapy RTTNews · Oct 29, 2026
- Earnings Preview: Bristol Myers Squibb (BMY) Q3 Earnings Expected to DeclineZacks · Oct 22, 2026
- BioMarin Pharmaceutical (BMRN) Earnings Expected to Grow: Should You Buy?Zacks · Oct 19, 2026
- Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Value StockZacks · Oct 13, 2026
The company
BioMarin is a leading, global rare disease biotechnology company focused on delivering medicines for people living with genetically defined conditions. Founded in 1997, the San Rafael, California-based company has a proven track record of innovation, with nine commercial therapies and a strong clinical and preclinical pipeline. Using a distinctive approach to drug discovery and development, BioMarin seeks to unleash the full potential of genetic science by pursuing category-defining medicines that have a profound impact on patients.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-GS
- Region
- North America
- Website
- biomarin.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.